Mangalam Drugs & Organics Limited (MANGALAM.BO)
INR 117.55
(-0.34%)
INR 117.55
(-0.34%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 174.94 Million INR | -21.38% |
| 2022 | 109.88 Million INR | -50.93% |
| 2021 | 491.44 Million INR | -18.04% |
| 2020 | 579.77 Million INR | 163.02% |
| 2019 | 248.74 Million INR | 152.14% |
| 2018 | 99.97 Million INR | -81.09% |
| 2017 | 476.95 Million INR | 0.68% |
| 2016 | 462.24 Million INR | 24.75% |
| 2015 | 377.2 Million INR | 103.59% |
| 2014 | 171.58 Million INR | 124.28% |
| 2013 | 98.46 Million INR | 369.66% |
| 2012 | -28.37 Million INR | -118.87% |
| 2011 | 150.38 Million INR | 14.48% |
| 2010 | 131.36 Million INR | 15.44% |
| 2009 | 111.37 Million INR | 17.34% |
| 2008 | 96.98 Million INR | 36.91% |
| 2007 | 70.83 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 81.9 Million INR | -29.8% |
| 2023 Q1 | -34.54 Million INR | -4.93% |
| 2023 FY | - INR | -21.38% |
| 2023 Q4 | 116.96 Million INR | 67.62% |
| 2023 Q3 | 69.77 Million INR | 213.47% |
| 2023 Q2 | 22.26 Million INR | 164.43% |
| 2022 Q3 | 66.03 Million INR | -21.69% |
| 2022 FY | - INR | -50.93% |
| 2022 Q4 | -32.92 Million INR | -149.86% |
| 2022 Q1 | 103.82 Million INR | 68.99% |
| 2022 Q2 | 84.32 Million INR | -18.78% |
| 2021 Q2 | 137.61 Million INR | 26.59% |
| 2021 Q4 | 61.44 Million INR | -57.07% |
| 2021 Q1 | 108.71 Million INR | 25.81% |
| 2021 Q3 | 143.12 Million INR | 4.0% |
| 2021 FY | - INR | -18.04% |
| 2020 Q1 | 142.72 Million INR | 290.52% |
| 2020 FY | - INR | 163.02% |
| 2020 Q3 | 138.71 Million INR | -24.22% |
| 2020 Q4 | 86.4 Million INR | -37.71% |
| 2020 Q2 | 183.05 Million INR | 28.26% |
| 2019 FY | - INR | 152.14% |
| 2019 Q1 | 54.93 Million INR | 432.42% |
| 2019 Q4 | 36.54 Million INR | -34.94% |
| 2019 Q2 | 61.5 Million INR | 11.96% |
| 2019 Q3 | 56.17 Million INR | -8.67% |
| 2018 FY | - INR | -81.09% |
| 2018 Q4 | -16.52 Million INR | -74.36% |
| 2018 Q3 | -9.47 Million INR | -116.97% |
| 2018 Q2 | 55.86 Million INR | 14.23% |
| 2018 Q1 | 48.9 Million INR | -49.13% |
| 2017 Q3 | 132.56 Million INR | -11.12% |
| 2017 Q2 | 149.15 Million INR | 50.52% |
| 2017 FY | - INR | 0.68% |
| 2017 Q1 | 99.09 Million INR | -29.36% |
| 2017 Q4 | 96.13 Million INR | -27.48% |
| 2016 Q2 | 106.74 Million INR | 12.43% |
| 2016 Q1 | 94.94 Million INR | -11.0% |
| 2016 Q4 | 140.28 Million INR | 16.23% |
| 2016 FY | - INR | 24.75% |
| 2016 Q3 | 120.69 Million INR | 13.07% |
| 2015 Q1 | 71.59 Million INR | 160.76% |
| 2015 Q2 | 103.19 Million INR | 44.14% |
| 2015 FY | - INR | 103.59% |
| 2015 Q4 | 106.68 Million INR | 19.76% |
| 2015 Q3 | 89.07 Million INR | -13.68% |
| 2014 Q2 | 58.28 Million INR | 62.82% |
| 2014 Q3 | 50.05 Million INR | -14.13% |
| 2014 FY | - INR | 124.28% |
| 2014 Q4 | 27.45 Million INR | -45.15% |
| 2014 Q1 | 35.79 Million INR | -41.44% |
| 2013 Q1 | -26.12 Million INR | -427.16% |
| 2013 Q2 | 25.2 Million INR | 196.48% |
| 2013 FY | - INR | 369.66% |
| 2013 Q4 | 61.12 Million INR | 59.76% |
| 2013 Q3 | 38.26 Million INR | 51.82% |
| 2012 Q1 | -27.23 Million INR | -242.33% |
| 2012 FY | - INR | -118.87% |
| 2012 Q4 | -4.95 Million INR | -142.55% |
| 2012 Q3 | 11.64 Million INR | 248.86% |
| 2012 Q2 | -7.82 Million INR | 71.28% |
| 2011 FY | - INR | 14.48% |
| 2011 Q4 | 19.13 Million INR | -50.51% |
| 2011 Q3 | 38.66 Million INR | 0.0% |
| 2010 FY | - INR | 15.44% |
| 2009 FY | - INR | 17.34% |
| 2008 FY | - INR | 36.91% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | 98.608% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 74.368% |
| Sigachi Industries Limited | 883.39 Million INR | 80.196% |
| Bal Pharma Limited | 345.59 Million INR | 49.378% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 97.45% |
| Medico Remedies Limited | 150.37 Million INR | -16.337% |
| Lasa Supergenerics Limited | -65.08 Million INR | 368.817% |
| Venus Remedies Limited | 711.8 Million INR | 75.422% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 104.689% |
| Alpa Laboratories Limited | 86.12 Million INR | -103.126% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 88.813% |
| Shilpa Medicare Limited | 2.58 Billion INR | 93.24% |
| Aarti Drugs Limited | 3.24 Billion INR | 94.615% |
| Lupin Limited | 36.96 Billion INR | 99.527% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.717% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.689% |
| Windlas Biotech Limited | 781.72 Million INR | 77.62% |
| Suven Life Sciences Limited | -992.78 Million INR | 117.622% |
| Eris Lifesciences Limited | 6.98 Billion INR | 97.496% |
| Valiant Laboratories Limited | 12.73 Million INR | -1273.31% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 98.126% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 106.2% |
| Ipca Laboratories Limited | 13.29 Billion INR | 98.685% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 88.172% |
| Achyut Healthcare Limited | 524 Thousand INR | -33286.641% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.874% |
| Bajaj HealthCare Limited | 444.51 Million INR | 60.643% |
| RPG Life Sciences Limited | 1.28 Billion INR | 86.348% |
| Mankind Pharma Limited | 28.09 Billion INR | 99.377% |
| Laurus Labs Limited | 8 Billion INR | 97.815% |
| Piramal Pharma Limited | 13.05 Billion INR | 98.66% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 59.341% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 99.5% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 98.181% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 98.458% |
| Unichem Laboratories Limited | 742.35 Million INR | 76.434% |
| Sequent Scientific Limited | 549.8 Million INR | 68.18% |
| Novartis India Limited | 1.26 Billion INR | 86.217% |
| Wanbury Limited | 985.49 Million INR | 82.248% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 96.26% |
| Wockhardt Limited | 1.08 Billion INR | 83.801% |
| Themis Medicare Limited | 562.6 Million INR | 68.904% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 45.914% |
| Jubilant Pharmova Limited | 8 Billion INR | 97.815% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 97.451% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.802% |
| Divi's Laboratories Limited | 25.43 Billion INR | 99.312% |
| NATCO Pharma Limited | 18.79 Billion INR | 99.069% |
| Gufic Biosciences Limited | 1.48 Billion INR | 88.183% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 93.288% |
| Ind-Swift Limited | 1.06 Billion INR | 83.574% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 94.196% |
| FDC Limited | 4.4 Billion INR | 96.025% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 311.474% |
| Granules India Limited | 8.6 Billion INR | 97.967% |
| Medicamen Biotech Limited | 245.66 Million INR | 28.785% |
| Alkem Laboratories Limited | 24.19 Billion INR | 99.277% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 92.577% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -1239.351% |
| Brooks Laboratories Limited | 41.72 Million INR | -319.253% |
| Megasoft Limited | 284.73 Million INR | 38.557% |
| ZIM Laboratories Limited | 462.09 Million INR | 62.141% |
| Strides Pharma Science Limited | 3.76 Billion INR | 95.353% |
| Neuland Laboratories Limited | 4.74 Billion INR | 96.316% |
| Morepen Laboratories Limited | 1.72 Billion INR | 89.864% |
| Hikal Limited | 2.69 Billion INR | 93.502% |
| Indoco Remedies Limited | 2.64 Billion INR | 93.391% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 95.525% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 39.133% |
| Hester Biosciences Limited | 539.47 Million INR | 67.571% |